Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy ; volume:11 ; number:1 ; day:8 ; month:1 ; year:2021 ; pages:1-8 ; date:12.2021
Scientific reports ; 11, Heft 1 (8.1.2021), 1-8, 12.2021
- Urheber
-
Anand, Kartik
Patel, Tejal
Niravath, Polly
Rodriguez, Angel
Darcourt, Jorge
Belcheva, Anna
Boone, Toniva
Ensor, Joe
Chang, Jenny
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-020-80081-y
- URN
-
urn:nbn:de:101:1-2021020520552582275953
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anand, Kartik
- Patel, Tejal
- Niravath, Polly
- Rodriguez, Angel
- Darcourt, Jorge
- Belcheva, Anna
- Boone, Toniva
- Ensor, Joe
- Chang, Jenny
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer